Safety analysis of high‐dose methotrexate in pediatric non‐Hodgkin lymphomas. Issue 11 (7th September 2022)

• Record Type: Journal Article
• Authors: Bernhardt, M. Brooke; Brown, Austin L.; Grim, Austyn T.; Scheurer, Michael E.; El‐Mallawany, Nader Kim; Ozuah, Nmazuo W.
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-07
• Subjects: childhood cancer -- methotrexate -- non‐Hodgkin lymphoma; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29940
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: High‐dose methotrexate (HD‐MTX) with rigorous supportive care is essential to the treatment of pediatric non‐Hodgkin lymphomas (NHL). We describe the safety and tolerability of HD‐MTX in patients with NHL treated at our center. In our cohort of 46 patients, the majority had at least one course of delayed clearance and/or creatinine elevation. Additionally, more than one‐third of patients experienced an episode of grade ≥3 mucositis. Creatinine elevations and delayed clearance were independently associated with subsequent grade ≥3 mucositis. We advocate for greater availability of methotrexate monitoring to allow dose escalation of this essential modality around the world.